Denied on prior authorisation twice, approved on the third attempt after a peer-to-peer, and the only thing that changed was who was doing the talking.
The narrow version of the question is what actually works on a prior-authorisation denial, as opposed to the list of things that sound like they should work.
Practical detail welcome, however dull — the duller the better.
ingrid_STO said:Denied on prior authorisation twice, approved on the third attempt after a peer-to-peer, and the only thing that changed was who was doing the…
Financial impact of cost and coverage weight loss beyond medication cost:
- Groceries: SAVED $278/month (eating less)
- Restaurants: SAVED $188/month (fewer meals out)
- Alcohol: SAVED $138/month (stopped drinking)
- Life insurance: Premium REDUCED by $48/month (lower BMI)
- Copays: SAVED $78/month (fewer BP/cholesterol meds)
Net impact after medication cost: approximately BREAKING EVEN. The medication pays for itself through reduced food spending and healthcare costs. This surprised me.
FDA_TrackerJim said:Financial impact of cost and coverage weight loss beyond medication cost: Groceries: SAVED $278/month (eating less) Restaurants: SAVED $188/month…
Telehealth prescriber review for cost and coverage: I've used 3 different telehealth platforms to get my GLP-1 prescription. Comparison:
| Feature | Platform A | Platform B | Platform C |
|---|---|---|---|
| Initial Consult | $49 | $89 | $0 |
| Monthly Follow-up | $39 | Included | $49 |
| Prescription Speed | Same day | 24-48 hours | Same day |
| Lab Monitoring | Required | Optional | Required |
I settled on the one that required labs — it shows they care about safety, not just prescribing volume.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View Resultsingrid_STO said:Denied on prior authorisation twice, approved on the third attempt after a peer-to-peer, and the only thing that changed was who was doing the…
Second this. I had assumed I was the exception until I read this.
From the other side of the consultation, briefly.
ingrid_STO said:...regarding the discontinuation data for cost and coverage...
I want to reframe the discontinuation narrative. We don't say "insulin fails because blood sugar rises when you stop it." We don't say "antihypertensives fail because BP goes up without them."
Why do we apply different logic to anti-obesity medications? The answer is stigma. We still, unconsciously, believe obesity is about willpower rather than biology. The discontinuation data actually PROVES it's a chronic biological condition requiring ongoing treatment.
This reframing isn't semantic — it has implications for insurance coverage, treatment duration, and patient expectations.